William Blair analyst Andrew Brackmann has reiterated their bullish stance on MDXH stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Brackmann has given his Buy rating due to a combination of factors tied to MDxHealth’s growth trajectory and execution. He notes that the slight fourth-quarter revenue shortfall and softer AEBITDA were mainly driven by temporary year-end and ExoDx integration timing effects, rather than any deterioration in the company’s core operations or demand profile.
Looking ahead to 2026, he highlights the company’s reaffirmed guidance of strong revenue expansion and its positioning for sustainable, profitable growth. Brackmann also points to upcoming catalysts, including deeper leverage of the combined ExoDx and MDxHealth customer base and clinical data from the GPS ProMPT study, while emphasizing that the current valuation at roughly 2x next-12-month revenue does not fully reflect the company’s growth potential and commercial platform, supporting his positive view on the shares.
Brackmann covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, BillionToOne, Inc. Class A, and QuidelOrtho. According to TipRanks, Brackmann has an average return of 16.1% and a 59.46% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $7.00 price target.